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Abstract: Diagnosis of salivary gland neoplasms is often challenging due to their high morphological
diversity and overlaps. Several recurrent molecular alterations have been described recently, which can
serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). How-
ever, current sequential molecular testing can be expensive and time consuming. In order to facilitate the
diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing
panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of
27 genes involved in salivary gland neoplasms. Here we present the validation of the ”SalvGlandDx”
panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against
the standard methods currently used at our institution. In a second part we describe selected unique
cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular
characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarci-
noma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid
adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma,
whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block
specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma
previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition,
features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma
of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1,
SNX9-PRKD1 and ATL2-PRKD3, are described.
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Abstract 
Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent 
molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. 
NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate 
the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the 
detection of mutations, fusions and gene expression levels (including NR4A3 ) of 27 genes involved in salivary gland neoplasms. Here 
we present the validation of the “SalvGlandDx” panel on FFPE histological specimen including fine needle aspiration (FNA) cell 
block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in 
which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary 
gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7 - NTRK2 fusion, a highly uncommon 
spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid 
carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the 
∗ Corresponding author: Niels J. Rupp, MD, Department of Pathology and Molecular 
Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland, 
Tel. + 41 44 255 50 91, Fax. + 41 44 255 44 40 
E-mail address: niels.rupp@usz.ch (N.J. Rupp). 
✩ 
✩ Funding: MH received institutional funding from Roche outside the submitted work. 
NJR discloses an advisory board function and receipt of honoraria from F. Hoffmann-La 
Roche AG. The “SalvGlandDx” panel has been developed by a grant from the Iten-Kohaut- 
Foundation / University Hospital Zurich Foundation to NJR. 
✩✩ Conflict of interest: All other authors declare that they have no conflict of interest. 
Received 31 January 2021; received in revised form 21 March 2021; accepted 22 March 
2021 
© 2021 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
https://doi.org/10.1016/j.neo.2021.03.008 
474 SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify 
therapeutic targets S.N. Freiberger et al. Neoplasia Vol. 23, No. xxx 2021 
FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of 
microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma 
/ cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A - PRKD1, 
SNX9-PRKD1 and ATL2-PRKD3, are described. 
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Introduction 
Salivary gland neoplasms often show a broad morphological spectrum 
including a variety of overlapping morphological patterns between different 
entities [1] . The diagnosis of these neoplasms can therefore pose significant 
difficulties. Especially on fine needle aspiration (FNA) or small biopsies, 
the differentiation between benign and low-grade malignant tumors can 
sometimes be impossible based on morphology alone [ 1 , 2 ]. In recent 
years, the knowledge about genomic landscapes of salivary gland neoplasms 
has significantly increased. Thereby, the distinct molecular aberrations are 
often highly specific to certain entities and can be exploited for diagnostic 
purposes [3] . The typical molecular aberrations encompass mutations, such 
as recurrent activating HRAS and/or PIK3CA mutations in epithelial- 
myoepithelial carcinoma [4] . Furthermore, increased expression levels of 
NR4A3 due to enhancer hijacking have been described recently as a hallmark 
of acinic cell carcinoma [5] . In addition, certain aberrations, such as 
NTRK3 fusions, which are highly recurrent in (mammary analogue) secretory 
carcinoma provide both a diagnostic [6] and therapeutic alteration for 
novel targeted inhibitors [7] . To further increase the diagnostic accuracy 
and facilitate diagnosis of salivary gland neoplasms, we here present a 
custom-designed comprehensive next generation RNA sequencing panel. 
This approach covers most of the common molecular alterations of salivary 
gland neoplasms in one test and can be reliably performed on FFPE 
tissue including biopsy or cell block specimen of FNAs. Therefore, the 
SalvGlandDx panel was recently implemented in our institutional diagnostic 
setting. 
Material and methods 
Panel design 
The target region was designed according to the current knowledge of 
molecular alterations (fusions and mutations) of salivary gland including 
odontogenic neoplasms ( Table 1 ) and covers known hotspot mutations and 
fusion genes. Furthermore, NR4A3 was included in the panel to measure 
mRNA expression levels. Moreover, NTRK1 / 2 / 3 fusions have recently gained 
high importance as therapeutic targets. Therefore, these genes were included 
as well. The assay was designed using the Archer Assay Designer software. 
Nucleic acid isolation from FFPE specimen 
Surplus FFPE material from surgical or cytologic specimen was used for 
nucleic acid isolation. The area of interest was marked by an experienced 
head and neck pathologist (NJR) on a representative H&E slide. Three 0.4 
mm 2 punch biopsies were then taken from the region of interest of the 
FFPE block. For FNA cell block specimen, four cuts of ten micrometers were 
cut and pooled. RNA was isolated using the Maxwell 16 LEV RNA FFPE 
Purification Kit and DNA was isolated using the Maxwell 16 FFPE Tissue 
LEV DNA Purification Kit (both Promega, Madison, WI, USA) according 
to the manufacturer’s manual. Quantification was done using the Qubit 
fluorometric assay (ThermoFisher Scientific, Waltham, MA, USA). 
Library preparation and next generation sequencing (NGS) 
Library preparation for the SalvGlandDx panel and the Archer 
FusionPlexSarcoma panel was performed according to the protocol of 
the Archer FusionPlex technology (ArcherDX, Boulder, CO, USA), using 
250 ng input RNA. Libraries were sequenced with 150bp paired-end 
on a NextSeq550. Library preparation for the custom-extended Archer 
FusionPlexSarcoma panel was performed according to the manufacturer’s 
protocol (ArcherDX, Boulder, CO, USA), using 250 ng input RNA. Libraries 
were sequenced on the Ion S5 system (ThermoFisher Scientific, Waltham, 
MA, USA). 
Library preparation for the Oncomine Focus Assay and Oncomine 
Comprehensive Assay v3 was performed according to the manufacturer’s 
manual (ThermoFisher Scientific, Waltham, MA, USA), using 10 ng or 20 
ng of input material. Libraries were templated on Ion 540 chips using the 
Ion Chef Instrument and sequenced on the Ion S5 system (ThermoFisher 
Scientific, Waltham, MA, USA). 
Fluorescence in situ hybridization (FISH) 
Two µm thick sections were incubated with dual color break apart (bap) 
FISH probes for EWSR1 ( Abbott Molecular Vysis LSI EWSR1 (22q12) bap, 
Abbott Park, IL, USA ), ETV6 ( Abbott Molecular Vysis ETV6 bap, Abbott 
Park, IL, USA), MAML2 (bap Zytovision, Bremerhaven, Germany), MYB 
(bap Zytovision, Bremerhaven, Germany), MYBL1 (bap Empire Genomics, 
Williamsville, NY, USA), NTRK2 (bap Zytovision, Bremerhaven, Germany) 
and SS18 (bap Abbott molecular, Abbott Park, IL, USA) according to the 
manufacturer’s protocol. 50 non-overlapping nuclei were analyzed using a 
fluorescence microscope (Zeiss Axioskop) with a 100-fold magnification oil 
objective. Pictures with Z-stacks of 20 images with 0.5 µm step distance were 
performed. Positive FISH was defined as at least 15% cells with break-apart 
and /or split signals. 
Sanger sequencing (PRKD1) 
DNA was amplified using custom primers covering the PRKD1 p.E710 
hotspot. The resulting products were purified using the Qiagen MiniElute 
PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced as described 
previously [51] using the following primers: 
Primer PRKD1 _F: 5 ′ -TGGAAGGTGACAAGATGCTACA-3 ′ 
Primer PRKD1 _R: 5 ′ -ACTGGAATGAAATTTTGGTGATTCT-3 ′ 
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Table 1 
Molecular alterations in salivary gland and odontogenic neoplasms according to current literature. 
Selected Molecular Aberrations 
Covered by SalvGlandDx Panel Entity 
Gene fusions 








PA, CA ex PA, MECA [ 8 , 9 ] 
PA, MECA [ 8 , 9 ] 
PA, MECA [ 8 , 9 ] 
PA,CA ex PA, MECA [9–11] 
MECA ex PA [10] 
PA [12] 
MECA, MECA ex PA [10] 




PA, CA ex PA [13] 
PA [12] 
PA (metastasizing) [14] 
MYB ∗ and MYBL1 ∗ fusions 
MYB-NFIB 
MYBL1-NFIB 
Adenoid-cystic carcinoma [ 15 , 16 ] 
Adenoid-cystic carcinoma [ 15 , 16 ] 
MAML2 ∗ fusions 
MAML2-CRTC1 
MAML2-CRTC3 
Mucoepidermoid carcinoma [17] 
Mucoepidermoid carcinoma [18] 
PRKD1 ∗-, PRKD2 ∗-, PRKD3 ∗- fusions 
ARID1A-PRKD1 
DDX3X-PRKD1 
PRKAR2A - PRKD1 
SNX9-PRKD1 
ATL2-PRKD3 
Polymorphous adenocarcinoma (including cribriform variant / CASG) [19–21] 
PAC, cribriform variant / CASG [20] 
PAC, cribriform variant / CASG [20] 
PAC, cribriform variant / CASG, current study 
PAC, cribriform variant / CASG, current study 
PAC, classical variant, current study 
SS18 ∗ fusions 
SS18-MEF2C 
SS18-ZBTB7A 
Microsecretory adenocarcinoma (incl. potential spectrum) [ 22 , 22 ] and current study 
MSANTD3 ∗ fusions 
HTN3-MSANTD3 Acinic cell carcinoma [23] 





Intraductal carcinoma [24] 
Intraductal carcinoma [24] 
Intraductal carcinoma [25] 
Secretory carcinoma [26] 




Secretory carcinoma [6] 
Secretory carcinoma [27] 
Secretory carcinoma [28] 





Clear cell (odontogenic) carcinoma [29] 
Clear cell (odontogenic) carcinoma [30] 
Clear cell (odontogenic) carcinoma [31] 
Adamantinoma-like Ewing family tumor / sarcoma [32] 




NUT carcinoma [33] 
NUT carcinoma [34] 
NUT carcinoma [35] 
NTRK1 ∗-, NTRK2 ∗-, NTRK3 ∗ fusions 
ETV6-NTRK3 Secretory carcinoma [6] 
NTRK2-ZCCHC7 Adenocarcinoma NOS, current study 
Gene mutations 
AKT1 p.E17 Epithelial-myoepithelial carcinoma [4] 
Intraductal papillary mucinous neoplasm [36] 
Salivary mucinous adenocarcinoma [37] 
( continued on next page ) 
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Table 1 ( continued ) 
Selected Molecular Aberrations 
Covered by SalvGlandDx Panel 
Entity 
CTNNB1 p.I35, p.Q28 Basal cell adenoma [ 38 , 39 ] 
SMO p.W535, p.L412 Ameloblastoma [40] 
KRAS p.G12, p.G13, p.Q61 Adenomatoid odontogenic tumor [41] , mucoepidermoid carcinoma [42] 
PRKD1 p.E710 Polymorphous adenocarcinoma [19] (including cribriform variant) [43] 
BRAF p.V600 Intraductal carcinoma [25] , sialadenoma papilliferum [44] , ameloblastoma [40] 
HRAS p.G12, p.G13, p.Q61 Epithelial-myoepithelial carcinoma [4] , intraductal carcinoma [45] , salivary duct carcinoma 
[46] , Sialadenoma papilliferum [47] 
PIK3CA p.E542, p.E545, p.H1047 Salivary duct carcinoma [48] , epithelial-myoepithelial carcinoma [4] , sclerosing polycystic 
adenosis / adenoma [49] , adenoid-cystic carcinoma (current study) 
NRAS p.G12, p.G13, p.Q61 Salivary duct carcinoma [46] 
Gene expression 
NR4A3 upregulation (due to enhancer 
hijacking) 
Acinic cell carcinoma [ 5 , 50 ] 
∗For each covered gene, also rare or 
novel fusion partners can be detected 
PA = Pleomorphic adenoma, CA ex PA = Carcinoma ex pleomorphic adenoma, MECA = Myoepithelial carcinoma, PAC = Polymorphous 
adenocarcinoma, CASG = cribriform adenocarcinoma of salivary gland 
Immunohistochemistry 
Immunohistochemical stainings were performed as described previously 
[52] , using the monoclonal primary anti-NUT antibody (clone C52B1, 
1:200, Cell Signaling Technology, Danvers, MA, USA) and the 
monoclonal anti-NR4A3 (NOR-1) antibody (clone H-7, 1:25, Santa 
Cruz Biotechnology, Inc, Dallas, TX, USA), applying the automated Leica 
Bond III staining system (Leica Biosystems, Nussloch, Germany). The 
Ventana Benchmark staining system (Oro Valley, AZ, USA) was applied 
for the following primary antibodies: p63 (clone 4A4, prediluted, Ventana, 
Oro Valley, AZ, USA), p40 (clone BC24, 1:100, Zytomed Systems, Berlin, 
Germany), panTRK (clone EPR17341, 1:100, Abcam, Cambridge, UK), 
CD117 (clone YR145, 1:200, Cell Marque Lifescreen Ltd., Rocklin, CA, 
USA), Ki-67 (clone 30-9, prediluted, Ventana, Oro Valley, AZ, USA), S100 
(polyclonal, 1:2000, DAKO A/S, Jena, Germany), DOG-1 (clone SP31, 
1:50 Invitrogen, Carlsbad, CA, USA). 
Data analysis 
For the SalvGlandDx panel, the sequencing output bcl files were 
converted to fastq format and analyzed by the Archer analysis software 
(ArcherDX, Boulder, CO, USA). Fusion calls were considered positive when 
they had at least three unique reads, five unique start sites and 10% reads 
covering the breakpoint. Mutation calls were considered positive when they 
had at least five reads covering the mutant allele, three unique start sites and at 
least 5% mutant allele frequency. For expression analysis, the Archer analysis 
software normalizes the expression of the panel genes to the average expression 
of four control genes. Relative gene expression is then visualized in a heat map 
and displayed as numerical values. 
For analysis of the Oncomine Assays, the IonReporter software 
(ThermoFisher Scientific, Waltham, MA, USA) was used with the generic 
filter settings. 
Sanger sequencing results were analyzed using visual inspection of the 
DNA sequence. 
Validation cohort ( Table 2 ) 
The cohort consisted of 32 FFPE samples (including three cell block 
specimen), mostly from salivary gland tumors. If salivary gland tumors 
with a certain alteration were not available, tests were applied to material 
from tumors with similar alterations. Moreover, the Archer SureShot 
sequencing controls (positive and negative control for ALK-RET-ROS1 
fusions, ArcherDX, Boulder, CO, USA), were included. 
Statistical analysis 
Student’s t-test was performed using GraphPad prism 8.0 to compare 
the NR4A3 normalized expression values between the different groups. A 
P value < 0.05 was considered statistically significant. Receiver operating 
characteristic (ROC) curve analysis was performed using IBM SPSS Statistics 
26. 
Ethics statement 
All patients, whose material was collected after 2015 signed a written 
informed consent for further use of their tissue and data. The current 
project is covered by approval from the local ethics review board (Kantonale 
Ethikkommision Zürich (BASEC-Nr. 2020-01663)), including a waiver for 
further material use collected prior to 2016. 
Results 
Panel validation 
To validate our custom designed SalvGlandDx panel, we used a cohort 
of 34 samples, including two sequencing controls ( Table 2 ) with alterations 
previously detected by current standard techniques for the different 
alterations (FISH, Sanger sequencing, immunohistochemistry, NGS). All 
samples passed the QC criteria set by the Archer analysis software. 
Fusion analysis 
Tumors with known fusions were available from 14 patients. Known 
fusions originate from FISH in five cases, NGS in five cases (Oncomine 
Focus or Comprehensive Assay v3, or Archer FusionPlexSarcoma panel), 
FISH plus NGS in one case and FISH plus IHC in one case. One case 
with NTRK1 fusion and one case with a NUTM1 fusion was confirmed 
by immunohistochemistry. Furthermore, the SureShot sequencing controls 
(positive and negative control for ALK-RET-ROS1 fusions) were used. 
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SG-4 Adenocarcinoma NOS / potential spectrum microsecretory adenocarcinoma 
SG-14 Polymorphous adenocarcinoma, cribriform variant / CASG 
SG-17 Adenoid-cystic carcinoma, high-grade transformation 
SG-24 Polymorphous adenocarcinoma, classical variant 
SG-25 Clear cell carcinoma 
SG-26 Polymorphous adenocarcinoma, classical variant 
SG-29 Acinic cell carcinoma 
SG-32 Adenoid-cystic carcinoma 
SG-35 Epithelial-myoepithelial carcinoma, solid-oncocytic variant (published before) [53] 
SG-36 Acinic cell carcinoma 
SG-37 Acinic cell carcinoma 
SG-38 Acinic cell carcinoma 
SG-39 Acinic cell carcinoma 
SG-41 Acinic cell carcinoma 
SG-42 Secretory carcinoma 
SG-44 Pleomorphic adenoma 
SG-46 Adenoid-cystic carcinoma 
SG-49 Adenocarcinoma NOS 
SG-51 Mucoepidermoid carcinoma, oncocytic variant (OMEC) 
SG-66 Carcinoma ex pleomorphic adenoma, minimal invasive 
SG-68 Acinic cell carcinoma, high-grade transformation 
SG-79 Epithelial-myoepithelial carcinoma, high-grade transformation 
SG-84 Basal cell adenoma 
SG-85 Acinic cell carcinoma, high-grade transformation 
VD-1 Melanoma 
VD-2 Melanoma 
VD-3 Lung adenocarcinoma 
VD-4 Lung adenocarcinoma 
VD-5 NUT carcinoma 
VD-6 NUT carcinoma 
VD-7 Basal cell carcinoma of the skin 
VD-8 Lipofibromatosis-like neural tumor 
NEG Archer SureShot negative control 
POS Archer SureShot positive control 
SG = Salivary gland tumor, CASG = Cribriform adenocarcinoma of salivary gland, VD = Validation sample, 
NEG = negative control, POS = positive control 
All known fusions were detected using the SalvGlandDx panel ( Table 3 ). 
Furthermore, fusion partners from genes shown to be rearranged in FISH 
could be determined. 
Mutation analysis 
To validate the SalvGlandDx panel for mutation analysis, we used eleven 
tumors with known mutations, previously detected by Sanger sequencing 
(3 cases) and amplicon-based DNA sequencing with Oncomine panels 
(8 cases). Furthermore, the SureShot sequencing controls (positive and 
negative control) were included, as their backbone cell line HTC-116 has 
known mutations in CTNNB1, KRAS and PIK3CA that are covered by the 
SalvGlandDx target region. With the SalvGlandDx panel, we were able to 
detect all mutations ( Table 4 ). 
Recurring variants in PIK3CA (p.S514Kfs ∗2) and PRKD3 (p.D304 = ) 
that were detected in the majority of all samples were flagged as artifacts. 
Moreover, several variants in EWSR1 , one variant in MYBL1 and one variant 
in MAML2 occurred in more than one sample, however not in the majority of 
samples. All of them were variants of unknown significance and were therefore 
not further investigated. 
Gene expression analysis 
Eight acinic cell carcinomas (six classical and two with high-grade 
transformation) and one secretory carcinoma (negative control) were stained 
with the NR4A3 antibody. All eight acinic cell carcinomas were positive 
( Fig. 1 A), while the secretory carcinoma showed no positive staining 
( Fig. 1 B). Likewise, the visual as well as the numerical normalized expression 
values (NEV) for all eight cases were significantly increased, while the values 
for the negative control were low. Moreover, we compared the normalized 
expression values of all 25 salivary gland neoplasms of the validation cohort 
and found a clear difference between positive (mean: NEV = 5.72 ± 1.48) 
and negative (mean: NEV = 0.1 ± 0.14) samples ( P < 0.0001, t -test, 
Fig. 1 C). A ROC curve analysis yielded an area under the curve (AUC) = 1 
with a sensitivity and specificity of 100% at an optimal discriminating 
cutoff of NEV = 2.32. Furthermore, visual inspection of the heatmap clearly 
distinguished positive and negative cases ( Fig. 1 D). 
Three samples from our validation cohort originated from cytological 
specimen, showing that the panel is suitable to process not only tissue biopsies 
but also material from cell block specimen of fine needle aspirations (SG- 
51: CRTC3-MAML2 fusion, SG-84: CTNNB1 mutation, SG-85: NR4A3 
expression) 
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Table 3 
Validation of known fusions. 





SG-4 FISH ( SS18 ) SS18 rearrangement SS18 - ZBTB7A 
SG-17 Amplicon sequencing (OCA) MYB - NFIB MYB - NFIB 
SG-25 FISH ( EWSR1 ) EWSR1 rearrangement EWSR1 - ATF1 
SG-32 FISH ( MYBL1 ) MYBL1 rearrangement MYBL1 - NFIB 
SG-42 IHC (panTRK), 
FISH ( ETV6 ) 
panTRK + 
ETV6 rearrangement 
ETV6 - NTRK3 
SG-44 Amplicon sequencing (OCA) FGFR1 - PLAG1 FGFR1 - PLAG1 
SG-46 FISH ( MYB ) MYB rearrangement MYB - NFIB 
SG-49 Customized Archer® FusionPlex Sarcoma panel 
FISH ( NTRK2 ) 
ZCCHC7 - NTRK2 
NTRK2 rearrangement 
ZCCHC7 - NTRK2 
SG-51 FISH ( MAML2 ) MAML2 rearrangement CRTC3 - MAML2 
SG-66 Archer® FusionPlexSarcoma panel HMGA2 - WIF1 HMGA2 - WIF1 
VD-4 Amplicon sequencing (OFA) KIAA1468 - RET KIAA1468 - RET 
VD-5 Amplicon sequencing (OCA) WHSC1L1 ( NSD3 )- NUTM1 NSD3 - NUTM1 
VD-6 IHC (NUT) NUT + BRD4 - NUTM1 
VD-8 IHC (panTRK) panTRK + TPM3 - NTRK1 
NEG Sequencing Control - - 
POS Sequencing Control CCDC6 - RET CCDC6 - RET 
SG = Salivary gland neoplasm, VD = Validation sample, NEG = negative control 
POS = positive control, OFA = Oncomine Focus Assay, OCA = Oncomine Comprehensive Assay, IHC = Immunohistochemistry 
Table 4 
Validation of known mutations 





SG-14 Sanger sequencing PRKD1 p.E710D PRKD1 p.E710D 
SG-17 Amplicon sequencing (OCA) PIK3CA p.E545K PIK3CA p.E545K 
SG-24 Sanger sequencing PRKD1 p.E710D PRKD1 p.E710D 
SG-26 Sanger sequencing PRKD1 p.E710D PRKD1 p.E710D 
SG-35 Amplicon sequencing (OCA) HRAS p.Q61R HRAS p.Q61R 
SG-79 Amplicon sequencing (OFA) AKT1 p.E17K AKT1 p.E17K 
SG-84 Amplicon sequencing (OFA) CTNNB1 p.I35T CTNNB1 p.I35T 
VD-1 Amplicon sequencing (OFA) BRAF p.V600E BRAF p.V600E 
VD-2 Amplicon sequencing (OFA) NRAS p.Q61K NRAS p.Q61K 
VD-3 Amplicon sequencing (OFA) KRAS p.G12C KRAS p.G12C 
VD-7 Amplicon sequencing (OCA) SMO p.L412F SMO p.L412F 
















SG = Salivary gland neoplasm; VD = Validation sample; NEG = negative control; POS = positive control; OFA = Oncomine TM 
Focus Assay; OCA = Oncomine TM Comprehensive Assay 
Practical application of SalvGlandDx panel on four unique cases 
Case 1: Purely oncocytic mucoepidermoid carcinoma (OMEC) 
The first case was a 33-years old male with a lump in the right 
parotid gland. Fine needle aspiration in our cytopathology department 
revealed a bland oncocytic neoplasm, rendering a broad differential diagnosis 
( Fig. 2 A, inset). The SalvGlandDx panel was performed on the cellblock 
specimen and detected a rare CRTC3-MAML2 fusion, highly specific to 
mucoepidermoid carcinoma. A MAML2 FISH showed > 15% split signals 
corroborating the detected MAML2 rearrangement ( Fig. 2 A, inset). After 
signing out the final diagnosis of OMEC, the preoperative consenting 
and surgical plan was adapted. The following resection specimen showed 
an infiltrative, purely oncocytic neoplasm with intersecting broad fibrous 
bands and focal eosinophilic secretions ( Fig. 2 A-B). Only miniscule areas of 
glandular differentiation with likewise intraluminal eosinophilic secretions 
could be observed ( Fig. 2 C), while mucocytes were completely absent 
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Fig. 1. High NR4A3 mRNA expression levels are specific to acinic cell carcinoma (ACC). (A) shows a conventional acinic cell carcinoma with blue zymogen 
granules and strong nuclear expression of NR4A3 immunohistochemistry (inset). (B) illustrates secretory carcinoma as most important differential diagnosis, 
negative for nuclear NR4A3 (inset). The normalized expression values (NEV) in (C) depict a significant difference between the n = 8 cases of acinic cell 
carcinomas (mean NEV = 5.72 ± 1.48) and the n = 17 remaining cases (mean NEV = 0.1 ± 0.14; P < 0.0001, t-test). The blue dotted line represents the 
optimal cutoff at NEV = 2.32, yielding an AUC = 1 with 100% sensitivity and specificity in a ROC curve analysis. (D) depicts representative heatmap of one 
NR4A3 positive case among negative cases. Scale bar 100 μm. 
Fig. 2. Case 1 : CRTC3-MAML2 fused oncocytic mucoepidermoid carcinoma (OMEC). (A) shows bland oncocytic cells in the fine needle aspiration cellblock 
specimen (upper inset). MAML2 FISH split signals can be appreciated in the corresponding inset. Resection specimen (below) depicts an infiltrating purely 
oncocytic neoplasia, intersecting the distinct fibrous bands. In (B) a magnification of the bland solid-oncocytic cell complexes is visualized with focal eosinophilic 
secretions (arrowheads). (C) shows very focal glandular differentiation with intraluminal secretions, however lacking the classical triphasic differentiation. In 
(D) the lack of typical alcianblue-positive mucocytes is illustrated, whereby the distinct spheroid violet reactivity was spatially correlating to the secretions 
(arrowheads). Immuohistochemical p63 expression was noted in a subset of cells (E). Scale bar 2.5 mm (overview), 100 μm (magnified insets). 
( Fig. 2 D). Furthermore, tumor manifestations were visible in close vicinity 
to peripheral nerve branches, however, without obvious perineural invasion. 
Immunhistochemical expression of p63 was positive in a subset of cells 
( Fig. 2 E). 
Case 2: Adenocarcinoma NOS with NTRK2 fusion and multiphasic 
growth pattern 
The second case was a 65 years-old male with a recurrent and infiltrating 
left parapharyngeal salivary gland tumor of exceptional morphology 
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Fig. 3. Case 2: ZCCHC7 - NTRK2 fused adenocarcinoma NOS with multiphasic growth pattern. In (A) a parapharyngeal lobulated, cellular neoplasm is 
shown infiltrating into adjacent skeletal muscle. NTRK2 FISH split signal can be observed (inset). Growth pattern encompassed microcystic (B), solid, epithel- 
myoepithelial carcinoma-like (arrowhead; C) and dissection of epithelioid cells in the distinct slate-gray background (D) pattern. In (E), tumoral pseudorosettes 
around vascular spaces are seen (arrowheads). Relevant immunohistochemical stains and accentuated alcianblue-PAS reactivity around the vascular spaces of 
the pseudorosettes is depicted in (F). Scale bar 2.5 mm (overview), 100 μm (magnified insets). 
( Fig. 3 A). The lobulated cellular mass showed dense intersecting and 
circumferential fibrous bands. The tumor cells were quite monomorphic 
and of one type, medium to large in size with clear chromatin, 
distinct nucleoli, eosinophilic and partially prominent clear cytoplasm with 
somewhat oncocytic aspect. Growth pattern encompassed a multiphasic 
microcystic, solid and cribriform morphology, with striking slate-grey 
extracellular deposits and stroma ( Fig. 3 B). Focal regions were reminiscent 
of epithelial-myoepithelial carcinoma with clearing of the more abluminal 
cells ( arrowhead ; Fig. 3 C); however, no true biphasic cell type differentiation 
could be noted by immunohistochemistry. Furthermore, a segmental 
morphology with dissecting epithelioid complexes into the described 
background was observed ( Fig. 3 D). Another growth pattern showed marked 
pseudorosettes ( arrowheads ; Fig. 3 E). Occasional mitotic figures were present. 
On immunohistochemistry SOX10 and S100 were diffusely expressed 
( Fig. 3 F), corroborating a salivary gland origin. Mammaglobin, CD117, 
NR4A3, DOG1, p63, p40, PLAG1 and androgen receptor were negative 
(data not shown). GATA3 showed very weak single cell reactivity. Pan- 
cytokeratin, and CK7 were diffusely positive. Interestingly, Ki-67 showed a 
distinct pattern with confluent garland-like peripheral proliferation fronts, 
leaving an impression of a punched-out proliferation-negative geographical 
center ( supplementary Fig. 1 ). PanTRK immunohistochemistry illustrated a 
very faint cytoplasmic and membranous reactivity, whereas Alcianblue-PAS 
staining depicted mucin depositions accentuated around the vascular spaces 
of the pseudorosettes ( Fig. 3 F). SalvGlandDx panel detected a ZCCHC7 - 
NTRK2 fusion, which has only been mentioned in an abstract, however 
without corresponding neoplasm type [54] . NTRK2 FISH confirmed this 
finding ( Fig. 3 A, inset). Although features were reminiscent of pleomorphic 
adenoma, a true chondro-myxoid matrix could not be detected. Furthermore, 
no change in cell type or size was observed. 
Case 3: Adenoid-cystic carcinoma with spindle cell and 
pseudoangiomatoid pattern 
The third case describes an adenoid-cystic carcinoma with very 
uncommon morphology. This tumor was excised due to a submucosal mass 
on the left cheek of a 55 years-old male patient. Histology showed a quite 
well circumscribed cellular neoplasm ( Fig. 4 A) with mixed morphology. 
The main part of the neoplasm consisted of bland spindle cells embedded 
in a chondro-myxoid like stroma intermingled with mature fat ( Fig. 4 B). 
Furthermore, a pseudoangiomatoid pattern could be noticed, besides myxoid 
nodules with fibrosis ( Fig. 4 C-D). Limited foci showed an adenoid-cystic 
like morphology ( Fig. 4 E) and focal neural invasion and infiltration of the 
peripheral soft tissue. Immunohistochemistry for p40 was diffusely positive 
without noticeable biphasic differentiation, reminiscent of a myoepithelial 
overgrowth; whereas CD117 was virtually absent. Ki-67 proliferation 
index was very low ( < 5%; Fig. 4 F). Although the tumor was resembling 
pleomorphic adenoma, the infiltrative pattern exceeded the classical observed 
features and rendered the differential diagnosis of carcinoma ex pleomorphic 
adenoma or unusual de novo adenoid-cystic carcinoma. Panel sequencing 
revealed a MYBL1-NFIB fusion, which was confirmed by corresponding split 
signals in MYBL1 FISH ( Fig. 3 A, inset). No rearrangement of PLAG1 or 
HMGA2 was detected. Final diagnosis was adenoid-cystic carcinoma with 
spindle cell and pseudoangiomatoid differentiation, mimicking pleomorphic 
adenoma. 
Case 4: SS18-ZBTB7A rearranged low-grade adenocarcinoma 
This case derives from the parotid gland of a 60 years-old male, who 
under went surger y due to a squamous cell carcinoma in the parotid gland. 
Besides, the resection specimen revealed a 7 mm diffusely infiltrating 
adenocarcinoma ( Fig. 5 A) with bland solid, cribriform, tubular and 
trabecular epithelial complexes ( Fig. 5 B-D). Focal oncocytic differentiation 
was observed, including rhabdoid- / histiocytoid-like single cells dissecting 
into the stroma ( Fig. 5 E). A prominent sclerotic stroma was evident in the 
background, while also distinct intraluminal bubbly secretions were noted 
( Fig. 5 E). Immunohistochemistry showed diffuse expression of SOX10, while 
DOG-1 showed an apical-membranous pattern, indicative of an intercalated 
duct differentiation. S100 was diffusely expressed in a heterogeneous 
pattern. A p40 staining was largely negative, including very limited 
areas of a biphasic pattern with single positive abluminal cells ( Fig. 5 F). 
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Fig. 4. Case 3: MYBL1-NFIB fused adenoid-cystic carcinoma with largely unusual morphology. (A) shows a quite well circumscribed cellular neoplasm. 
MYBL1 FISH shows split signals (inset). In (B) the bland spindle cells mixed with mature (probably infiltrated) fat and the prominent myxoid background 
is depicted. The pseudoangiomatoid pattern is represented in (C) with capillary-like structures. The fibro-myxoid nodules can be appreciated in (D) and (E) 
shows very limited foci of more conventional cribriform morphology. The diffuse p40 expression with monophasic pattern is visualized in (F), with CD117 
negativity and very low Ki-67 proliferation index. Scale bar 2.5 mm (overview), 100 μm (magnified insets). 
Fig. 5. Case 4: S S18-ZBTB7A fused low-grade adenocarcinoma. (A) shows diffusely infiltrating adenocarcinoma with split signals in SS18 FISH (inset). 
The magnification in (B) illustrates the solid growth of medium-sized atypical cells including subtle nucleoli and slightly oncocytic differentiation. In (C) 
the cribriform ductal differentiation is depicted, whereas (D) pictures the small irregular tubular complexes within a sclerotic stroma, reminiscent of tubular 
breast cancer. (E) outlines the more oncocytic single cells with a histiocytoid / rhabdoid differentiation (left arrowhead). The right arrowhead points to the 
intraglandular bubbly secretions. The relevant immunhistochemical stainings are shown in (F), whereas the lower p40 staining describes the focal biphasic 
differentiation in contrast to the negative upper staining representative for most of the tumor. Scale bar 2.5 mm (overview), 100 μm (magnified insets). 
SalvGlandDx panel showed a SS18-ZBTB7A fusion, corroborated by positive 
SS18 FISH ( Fig. 5 A, inset). The morphology and molecular profile 
matched with the single other published case, which has been reported as 
potential spectrum of the recently described microsecretory adenocarcinoma 
[22] . 
Identification of novel fusions involving the PRKD genes 
To identify fusion partners of the investigated PRKD genes, six cases 
of polymorphous adenocarcinoma including cribriform variant / cribriform 
adenocarcinoma of salivary gland (CASG) were identified from our archive 
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Table 5 
Clinicopathological features of investigated polymorphous adenocarcinomas (PAC) including cribriform variant / cribriform adenocarcinoma 
of salivary gland (CASG). 
Case 1 2 3 4 5 6 
Age 33 54 74 34 84 67 
Sex f m f m f m 
Localization Buccal Hard / soft palate Buccal, maxillary 
sinus 
Soft palate Parotid gland Soft palate 
Size 1.3 cm 0.9 cm 5.5 cm 1.1 cm 2.4 cm 0.5 cm 









variant / CASG 
PAC, cribriform 





PRKD1 p.E710D PRKD1 p.E710D PRKD1 p.E710D PRKAR2A-PRKD1 SNX9-PRKD1 ATL2-PRKD3 
Perineural 
invasion 
yes yes yes yes yes yes 
Metastases no no no yes, 
Neck, Level II-III, 
14 years after 
primary 
no no 










Follow-up NED, 74 
months 
NED, 39 months NED, 12 months NED, 243 months NED, 16 months NED, 3 months 
NED = no evidence of disease 
including consult cases and subjected to sequencing with the SalvGlandDx 
panel. Clinicopathological overview is depicted in Table 5 . 
Three cases (50%) with an origin in the oral mucosa showed an 
activating PRKD1 p.E710D mutation, of which two cases showed a classical 
polymorphous (low-grade) morphology ( Fig. 6 A). One case was a large 
polypoid tumor of 5.5 cm in the maxillary sinus and showed largely 
solid differentiation including prominent nuclear clearing, compatible with 
cribriform variant /CASG. Of note, besides focal typical glomeruloid growth, 
this case showed an uncommon basaloid morphology with extracellular 
basal membrane-like material reminiscent of basal cell adenocarcinoma 
( Fig. 6 B, inset). The other three cases showed PRKD gene fusions. One case 
showed a PRKAR2A - PRKD1 fusion and was metastasized to the neck lymph 
nodes 14 years after the primary tumor was resected from the soft palate. 
Morphology encompassed typical features of cribriform variant / CASG with 
solid, glomeruloid and focal papillary growth (case not shown). Another 
case harbored a SNX9-PRKD1 rearrangement and likewise represented a 
typical solid, glomeruloid and focal papillary architecture with calcifications 
as described in cribriform variant / CASG [55] ( Fig. 6 C). Remarkably, this 
tumor was located in the parotid gland without clinical evidence for any other 
manifestation. The remaining case showed an ATL2-PRKD3 fusion, however, 
was depicting a classical monophasic low-grade appearance similar to the first 
two cases with focal perineural invasion in the oral mucosa ( Fig. 6 D). 
Discussion 
With the validation of the known alterations in our cohort, we were able 
to design a custom NGS panel that facilitates the diagnosis and classification 
of salivary gland neoplasms with one single test. Well-known fusions as well as 
hotspot mutations and elevated gene expression of NR4A3 could reliably be 
detected not only in histological FFPE tissue, but also in cell block specimen 
of fine needle aspirations. The latter in particular may allow a more precise 
diagnosis and alleviate the need for core needle biopsy and/or incisional 
biopsy. To our knowledge this is the first validated panel that includes all 
relevant genes to detect specific alterations, including mutations, fusions and 
gene expressions on RNA level. While usually only single alterations can be 
tested at the time (e.g. FISH, IHC, Sanger sequencing), some commercially 
available NGS panels cover certain genes, however, not all of them within one 
assay. 
Besides the detection of relevant alterations for salivary gland neoplasm 
diagnosis and classification, our panel can reliably detect therapeutic targets, 
such as NTRK fusions. Here, NTRK inhibitors (e.g. larotrectinib, entrectinib) 
were recently shown to be effective in patients with NTRK fusions [ 56 , 57 ]. 
According to the ESMO guidelines, testing with an RNA-based NGS assay 
is preferred for these alterations [58] . 
High expression levels of NR4A3 were specifically associated with acinic 
cell carcinoma in our study, as described by Haller et al. [5] . In particular on 
FNA specimen, the diagnosis of acinic cell carcinoma can be hampered by 
high similarity to normal acinic cells [59] . Moreover, cases with high-grade 
morphology might not show the typical features. Our two cases with high- 
grade transformation could correctly be assigned to acinic cell carcinoma by 
the panel results, corroborated by positive NR4A3 immunohistochemistry. 
One case could already be diagnosed on the FNA specimen guided by high 
NR4A3 expression levels detected by the SalvGlandDx panel. The (high- 
grade) morphology on the FNA specimen was not specific; however, the 
diagnosis was confirmed on the histological specimen showing partial obvious 
classical (low-grade) differentiation. 
Case 1 showed an intriguing oncocytic mucoepidermoid carcinoma 
(OMEC), lacking the typical mucocytes and triphasic differentiation as 
recently described by Skalova et al. [60] and one similar case by Todorovic et 
al. [61] . The CRTC3-MAML2 fusion is highly specific to mucoepidermoid 
carcinoma [18] , whereas the detection on the cellblock specimen combined 
with the oncocytic morphology was sufficient for this diagnosis. Current data 
suggest that (purely) oncocytic and sclerosing variant of MEC are most likely 
low-grade neoplasms [ 62 , 63 ], which seem to show a more indolent biological 
behavior. However, one has to be aware that current grading schemes (e.g. 
AFIP and Brandwein-Gensler) might lead to a distinct appraisal [60] . Future 
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Fig. 6. Morphological comparison of PRKD1 p.E710D mutated and PRKD1/PRKD3 rearranged polymorphous adenocarcinoma (PAC) / cribriform 
adenocarcinoma of salivary gland (CASG). (A) shows classical monomorphic tubular and trabecular PAC complexes with diffuse infiltrative pattern including 
targetoid perineural invasion (arrowhead), a slate-grey stroma and an underlying PRKD1 p.E710D mutation. In (B) another case with PRKD1 p.E710D 
mutation derived from a maxillary sinus polypoid lesion is depicted, however illustrating a solid differentiation with prominent nuclear clearing reminiscent 
of papillary thyroid carcinoma, compatible with cribriform variant / CASG. In the insets focal perineural invasion (arrowhead) is shown and different 
growth patterns encompassing cribriform, glomeruloid, basaloid jigsaw-like and ductal-like. (C) illustrates the typical morphological spectrum of a (parotid 
gland) cribriform variant / CASG harboring a SNX9-PRKD1 fusion, including nuclear clearing of solid tumor complexes, perineural invasion (arrowhead), 
glomeruloid and papillary growth pattern as well as focal calcifications (insets). Of note, the stroma is sclerotic. (D) depicts a morphological similar case to 
(A), including targetoid perineural invasion (arrowhead) and slate-grey stroma, however harboring ATL2-PRKD3 fusion. Scale bar 100 μm. 
data will be needed to clarify this issue and potentially grade these subentities 
separately. 
The second case revealed a novel ZCCHC7 - NTRK2 fusion, which could 
be verified independently in other laboratories using NGS panel and a 
break-apart FISH assay. That approach shows, that directed molecular 
testing can, albeit in rare instances, reveal targetable alterations. The 
uncommon mixed morphology was not assignable to a known entity. 
The immunohistochemical phenotype, encompassing SOX10 and S100 
co-expression, corroborated the diagnosis of a salivary gland neoplasm. 
Although the tumor showed areas reminiscent of pleomorphic adenoma 
(PA), including the variety of growth patterns and distinct background, no 
true chondro-myxoid matrix or fibrous (pseudo)capsule could be observed. 
Furthermore, the cell type was overall too monomorphic, large and atypical 
in comparison to a conventional PA. The observed infiltrative growth pattern 
on the resection specimen, without a typical change of cell type or cell 
overgrowth rather represents a distinct clonal entity than a carcinoma ex 
pleomorphic adenoma in our view. Despite similarities to a myoepithelial- 
like immunophenotype [64] , the presence of abundant ductal structures 
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did not admit diagnosis of a (secretory) myoepithelial carcinoma [ 65 , 66 ]. 
An uncommon variant of secretory carcinoma, involving commonly ETV6- 
NTRK3 fusions, could not be diagnosed due to a distinct morphology, 
molecular and immunohistochemical profile (e.g. mammaglobin negative) 
[6] . Altogether, the observed cell type shows similarities to striated ducts 
in normal salivary gland tissue, however the immunophenotypes cannot 
be matched [67] . Besides, the distinct background and single cell type 
showing different growth patterns could lead to the differential diagnosis 
of polymorphous adenocarcinoma; however, the comprehensive profile does 
not fit in this category [68] . NTRK2 fusions are extremely rare and even 
less common than NTRK1 and NTRK3 fusions. In two recently published 
clinical trials investigating the NTRK inhibitors entrectinib and larotrectinib 
in solid tumors, only one out of 54 and 55 participants, respectively, harbored 
a NTRK2 fusion without mentioning the tumor entity [ 56 , 57 ]. We were not 
able to find a specific report of a NTRK2 fused salivary gland neoplasm in 
the literature at the current time. Morphology encompassed a single cell type 
with multiphasic and infiltrative growth pattern, whereas further cases have 
to elucidate a potential recurrent nature of this outstanding type of neoplasm. 
The third case showed a very uncommon morphology, which could 
lead to a misinterpretation of pleomorphic adenoma. Parallel sequencing 
of the fusion genes with the described panel could thereby help to further 
corroborate a carcinoma ex pleomorphic adenoma, which typically harbors 
PLAG1 or HMGA2 fusions [ 69 , 70 ]. MYBL1-NFIB rearrangements can be 
detected in up to 24% of adenoid-cystic carcinoma and are highly specific for 
this tumor entity [ 15 , 16 ]. Overall, this fusion corroborates the diagnosis of 
adenoid-cystic carcinoma although the morphology was largely unusual. The 
molecular finding is in line with a recently published similar case, however 
obscuring its origin by illustrating squamous differentiation [61] . 
The fourth case was initially classified as adenocarcinoma NOS, as it 
did not fit to a known category. Sequencing revealed a SS18-ZBTB7A 
fusion, which has been recently described in a potential spectrum of 
microsecretory adenocarcinoma (MSA), typically harboring MEF2C-SS18 
fusions and occurring in the oral cavity [22] . Interestingly, it was similarly 
small ( < 1 cm) and located in the parotid gland likewise as the only case 
with this fusion described by Bishop et al. [22] . Our case showed the 
identical fusion ( SS18 exon 10, ZBTB7A exon 2), a similar morphological 
and immunohistochemical profile (largely negative for p63 and p40). 
In addition, we describe a DOG1 expression, indicative of a potential 
intercalated duct differentiation [71] ; however, no information about DOG1 
expression in bona fide MSA is available. Due to an identical morphological, 
immunohistochemical and molecular profile, our case corroborates that this 
tumor type is a recurrent finding. However, further cases have to elucidate 
whether this is a genuine spectrum of MSA or a separate entity sharing some 
features with MSA. 
PRKD1 mutations were specific to the spectrum of polymorphous 
adenocarcinoma (PAC). Most of the classical PAC did show a recurrent 
PRKD1 p.E710D mutation, whereas one (metastasized) cribriform variant 
/ CASG did show a previously undescribed PRKAR2A - PRKD1 fusion . 
However, one case of a classical PAC did show an ATL2-PRKD3 fusion and 
one case of a non-metastasized cribriform variant / CASG with uncommon 
basaloid features harbored a PRKD1 p.E710D mutation, corroborating the 
findings from Sebastiao et al. that the type of aberration is not entirely specific 
for classical PAC or cribriform variant / CASG [43] . Moreover, the case 
harboring the SNX9-PRDK1 fusion was located in the parotid gland without 
evidence of other manifestations, underscoring the previous finding that this 
entity can also occur rarely in the major salivary glands [21] . Polymorphous 
adenocarcinoma is rarely observed in the sinonasal tract [72] , whereas 
cribriform variant /CASG has to the best of our knowledge not been described 
to involve the maxillary sinus, yet. Morphological classification of these 
neoplasms has been difficult among a large multicenter study [21] . However, 
molecular analysis can help to assign a certain tumor with uncommon 
morphology or on a small biopsy /FNA to the described spectrum. Mutations 
in the other investigated genes are generally less specific. However, there are 
only exceedingly rare reports of a benign salivary gland neoplasm harboring 
an activating HRAS mutation (in this case: sialadenoma papilliferum) [47] . 
With a compatible morphology, HRAS mutation is strongly underscoring 
epithelial-myoepithelial carcinoma, even in uncommon variants [4] . 
We envision the SalvGlandDx panel as a useful all-in-one tool to diagnose 
and classify salivary gland neoplasms. With this panel, we can corroborate 
the findings from Todorovic et al. , who showed the importance of next 
generation sequencing in salivary gland neoplasms from different aspects 
[61] . The great advantage is thereby the simultaneous capturing of aberrant 
expression, gene mutations and fusions with the only need of RNA extraction, 
also reliably working on FFPE cell block specimen. One drawback might be 
uncovered individual fusions, such as ALK rearrangements, recently described 
in a small subset of intraductal carcinoma [73] . However, due to the design 
of the Archer FusionPlex technology, the panel can easily be amended in the 
future to include relevant emerging genes; however, keeping it as small as 
possible to optimize utilization on the sequencer. Nevertheless, this assay can 
significantly help to proper classify most of the salivary gland neoplasms, as it 
includes most of the recurrent gene aberrations known to date. Furthermore, 
it is able to simultaneously reveal potential molecular therapeutic targets such 
as NTRK and RET fusions, and can be applied on cellblock specimen of 
minimal invasive fine needle aspiration. 
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